U.S. Glioblastoma Market & Competitive Landscape (2018-2023) - ResearchAndMarkets.com

October 11, 2018

DUBLIN--(BUSINESS WIRE)--Oct 11, 2018--The “US Glioblastoma Market and Competitive Landscape - 2018” report has been added to ResearchAndMarkets.com’s offering.

The latest research US Glioblastoma Market and Competitive Landscape - 2018, provides comprehensive insights into Glioblastoma pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares. This study accurately estimates and forecast Glioblastoma market size and drug sales. This research also provides insights into Glioblastoma epidemiology and late stage pipeline.

The research is classified into following sections - Glioblastoma overview with definitions, symptoms, etiology, diagnosis, treatment options; Glioblastoma pipeline insights covering late stage clinical trials pipeline; Glioblastoma prevalence trends by countries; Glioblastoma market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.

Research Scope

Glioblastoma pipeline: Find out the drugs in clinical trials for Glioblastoma by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company Glioblastoma epidemiology: Find out the prevalence of Glioblastoma in US; prevalence forecast to 2023 Glioblastoma products: Identify key products marketed and prescribed for Glioblastoma by brand name, by molecule, by company, by branded / generic, in US Glioblastoma market size: Find out the market size for Glioblastoma drugs in US; Find out how the market advanced from 2014 Glioblastoma drug sales: Find out the sales of Glioblastoma drugs in US Glioblastoma drugs sales forecast: Sales forecast for Glioblastoma drugs to 2023 in US Glioblastoma market share analysis: Find out the market shares of Glioblastoma drugs and outlook in US

For more information about this report visit https://www.researchandmarkets.com/research/wgv7l8/u_s_glioblastoma?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181011005304/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Brain Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/11/2018 04:49 AM/DISC: 10/11/2018 04:49 AM


Update hourly